<VariationArchive VariationID="17900" VariationName="APOB, 4-BP DEL, NT36491" VariationType="Deletion" Accession="VCV000017900" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-29" DateCreated="2019-06-22" MostRecentSubmission="2019-06-22">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="32939" VariationID="17900">
      <GeneList>
        <Gene Symbol="APOB" FullName="apolipoprotein B" GeneID="338" HGNC_ID="HGNC:603" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>2p24.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="21001429" stop="21044073" display_start="21001429" display_stop="21044073" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791767.1" start="52097" stop="94741" display_start="52097" display_stop="94741" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="21224300" stop="21266944" display_start="21224300" display_stop="21266944" Strand="-" />
          </Location>
          <OMIM>107730</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>APOB, 4-BP DEL, NT36491</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p24</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>4-BP DEL, NT36491</Name>
      </OtherNameList>
      <XRefList>
        <XRef Type="Allelic variant" ID="107730.0020" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff could not confirm the published nucleotide change on current reference sequence after review of PubMed 15984016.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="APOB, 4-BP DEL, NT36491 AND Familial hypobetalipoproteinemia 1" Accession="RCV001837441" Version="9">
        <ClassifiedConditionList TraitSetID="12438">
          <ClassifiedCondition DB="MedGen" ID="C4551990">Familial hypobetalipoproteinemia 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2005-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2005-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-06-22" MostRecentSubmission="2019-06-22">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15984016</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7229035</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="12438" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18459" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial hypobetalipoproteinemia 1</ElementValue>
                <XRef ID="MONDO:0014252" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, normotriglyceridemic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acanthocytosis with hypobetalipoproteinemia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHBL1</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FHBL</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2876" />
                <XRef ID="2876" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Individuals with biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction. Affected individuals typically have plasma total cholesterol, LDL cholesterol, and apo B levels below the fifth centile for age and sex. Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found. The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency. In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver. Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis. However, about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely.</Attribute>
                <XRef ID="NBK570370" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">33983694</ID>
                <ID Source="BookShelf">NBK570370</ID>
              </Citation>
              <XRef ID="C4551990" DB="MedGen" />
              <XRef ID="MONDO:0014252" DB="MONDO" />
              <XRef Type="MIM" ID="615558" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="39786" SubmissionDate="2019-06-19" DateLastUpdated="2019-06-22" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="107730.0020_HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC" title="APOB, 4-BP DEL, NT36491_HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC" />
        <ClinVarAccession Accession="SCV000039786" DateUpdated="2019-06-22" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2005-07-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with normotriglyceridemic hypobetalipoproteinemia (615558), obesity, and mental retardation, Homer et al. (2005) identified compound heterozygosity for 2 mutations in the APOB gene. One was a 4-bp deletion beginning at nucleotide 36491 in exon 26, predicted to result in a frameshift and incorporation of 5 new amino acids before encountering a premature termination codon at position 3053. This translated protein would be 66% of full-length apoB, which would allow for expression in the liver and for production of minute amounts of VLDL and LDL. Accordingly, the patient did not have failure to thrive or steatorrhea. The second mutation was a 29142T-A transversion in exon 23, resulting in a tyr1173-to-ter (Y1173X; 107730.0021) substitution. The translated Y1173X protein is predicted to be 25.8% of apoB100 and is not expressed in apoB-containing lipoproteins. Homer et al. (2005) suggested that the clinical features of ataxia, visual impairment, and probable neuropathy seen in the patient resulted from the inability to transport the active stereoisomer of vitamin E from the liver. These clinical features were similar to those seen in isolated vitamin E deficiency (VED; 277460). Homer et al. (2005) noted that the clinical features of this patient were similar to those of the patient reported by Malloy et al. (1981) (see 107730.0013).</Attribute>
              <Citation>
                <ID Source="PubMed">15984016</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">7229035</ID>
              </Citation>
              <XRef DB="OMIM" ID="615558" Type="MIM" />
              <XRef DB="OMIM" ID="277460" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Homer et al. (2005) suggested that the term 'normotriglyceridemic hypobetalipoproteinemia' is preferred to 'normotriglyceridemic abetalipoproteinemia' because abetalipoproteinemia (ABL; 200100) refers to the disorder caused by mutation in the MTP gene (157147).</Attribute>
              <Citation>
                <ID Source="PubMed">15984016</ID>
              </Citation>
              <XRef DB="OMIM" ID="200100" Type="MIM" />
              <XRef DB="OMIM" ID="157147" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="APOB" />
          </GeneList>
          <Name>APOB, 4-BP DEL, NT36491</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, NT36491</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="107730.0020" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="39786" TraitType="Disease" MappingType="Name" MappingValue="HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC" MappingRef="Preferred">
        <MedGen CUI="C4551990" Name="Familial hypobetalipoproteinemia 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

